These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18427539)

  • 41. [Treatment and long-term follow-up of post-anoxic myoclonus].
    Janszky J; Holló A; Halász P
    Orv Hetil; 2001 Sep; 142(38):2091-3. PubMed ID: 11697066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The nootropic and anxiolytic properties of different doses of piracetam].
    Voronina TA; Molodavkin GM; Borlikova GG; Ostrovskaia RU; Tushmalova NA; Naznamov GG
    Eksp Klin Farmakol; 2000; 63(2):9-11. PubMed ID: 10834086
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of nootropic agents on the brain bioelectrical activity and on the indices of neuromediator metabolism in the acute period of severe craniocerebral trauma].
    Madorskiĭ SV; Potapov AA; Piasetskaia MV; Shapova EV; Il'icheva RF
    Zh Vopr Neirokhir Im N N Burdenko; 1989; (3):29-35. PubMed ID: 2572097
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Piracetam: a novel therapy for autism?
    Paczynski M
    J Autism Dev Disord; 1997 Oct; 27(5):628-30. PubMed ID: 9403377
    [No Abstract]   [Full Text] [Related]  

  • 45. Piracetam and platelets--a review of laboratory and clinical data.
    Evers S; Grotemeyer KH
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():44-8. PubMed ID: 10338108
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study.
    Amieva H; Meillon C; Helmer C; Barberger-Gateau P; Dartigues JF
    PLoS One; 2013; 8(1):e52755. PubMed ID: 23326356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study.
    Enderby P; Broeckx J; Hospers W; Schildermans F; Deberdt W
    Clin Neuropharmacol; 1994 Aug; 17(4):320-31. PubMed ID: 9316679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dyslexia: clinical, neurophysiological and neuropsychological manifestations during the treatment with nootropil].
    Zavadenko NN; Rumiantseva MV; Tolstova VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):36-42. PubMed ID: 19491817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dynamics of cognitive and emotional-volitional disorders in children and adolescents with refractory epilepsy during the treatment with levetiracetam].
    Popov IuV; Iakovleva IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(5 Pt 2):48-52. PubMed ID: 23739514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Piracetam in combined pathogenetic therapy of recurrent duodenal ulcer].
    Tsimmerman IaS; Shchetkin DI
    Klin Med (Mosk); 2002; 80(1):48-53. PubMed ID: 11855320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy.
    Khani YA; Andermann F; Andermann E
    Epilepsia; 2005 Jul; 46(7):1145-6. PubMed ID: 16026569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The influence of piracetam on behavior and brain receptors in C57BL/6 and BALB/c mice: nootropic and anxiolytic effects].
    Kovalev GI; Kondrakhin EA; Salimov RM; Neznamov GG
    Eksp Klin Farmakol; 2013; 76(9):3-10. PubMed ID: 24432561
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pilot study to determine the hemodynamic safety and feasibility of magnesium sulfate infusion in children with severe traumatic brain injury.
    Natale JE; Guerguerian AM; Joseph JG; McCarter R; Shao C; Slomine B; Christensen J; Johnston MV; Shaffner DH
    Pediatr Crit Care Med; 2007 Jan; 8(1):1-9. PubMed ID: 17251875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [State of the hemostasis system and pathogenetic therapy of circulatory encephalopathy].
    Bekuzarova MR; Burd GS; Kolesnikova TI; Iasamanova AN; Kabanov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(6):35-8. PubMed ID: 11517473
    [No Abstract]   [Full Text] [Related]  

  • 55. [The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study].
    Mateo D; Giménez-Roldán S
    Neurologia; 1996 Jan; 11(1):16-9. PubMed ID: 8714171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"].
    Gomazkov OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):69-70. PubMed ID: 12378888
    [No Abstract]   [Full Text] [Related]  

  • 57. Cognitive recovery after severe traumatic brain injury in children/adolescents and adults: similar positive outcome but different underlying pathways?
    Tavano A; Galbiati S; Recla M; Bardoni A; Dominici C; Pastore V; Strazzer S
    Brain Inj; 2014; 28(7):900-5. PubMed ID: 24655151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Piracetam in the treatment of acute stroke.
    Orgogozo JM
    Pharmacopsychiatry; 1999 Mar; 32 Suppl 1():25-32. PubMed ID: 10338105
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative evaluation of the neuroprotective activity of phenotropil and piracetam in laboratory animals with experimental cerebral ischemia].
    Tiurenkov IN; Bagmetov MN; Epishina VV
    Eksp Klin Farmakol; 2007; 70(2):24-9. PubMed ID: 17523446
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The treatment of mild cognitive disorders].
    Zakharov VV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(12):121-5. PubMed ID: 24596976
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.